The city of Dallas, Texas, currently has 13 active clinical trials seeking participants for Type 2 Diabetes research studies.
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/21/2025
Locations: Cedar Health Research, LLC, Dallas, Texas
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Register for Updates
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
NCT06926842
Recruiting
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: The University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Overweight, Type 2 Diabetes, Obesity
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NCT06326047
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/27/2025
Locations: Velocity Clinical Res-Dallas, Dallas, Texas +1 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
NCT06579105
Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Research Site, Dallas, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874
Recruiting
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/23/2025
Locations: Velocity Clinical Res-Dallas, Dallas, Texas +1 locations
Conditions: Type 2 Diabetes (T2D)
Register for Updates
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas
Conditions: Type 2 Diabetes
Register for Updates
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
NCT06628362
Recruiting
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/14/2025
Locations: Velocity Clinical Research - Dallas, Dallas, Texas +1 locations
Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Register for Updates
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391
Recruiting
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
03/03/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas +2 locations
Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Register for Updates
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients with Type 2 Diabetes: STRONG-DM Study
NCT06593327
Recruiting
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
Gender:
ALL
Ages:
All
Trial Updated:
02/24/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
Register for Updates
DIALYSIS-TIR Study
NCT06042153
Recruiting
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Davita UT Southwestern - Oak Cliff, Dallas, Texas +2 locations
Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
Register for Updates
Assessing the Efficacy of Targeted Home Visits in the Management of Chronic Conditions
NCT05168605
Recruiting
The purpose of study is to evaluate whether home visit programs are an effective method for HTN and T2DM management as compared to standard of care clinic visits.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/30/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Hypertension, Type 2 Diabetes
Register for Updates
Polypill for Prevention of Cardiomyopathy
NCT06143566
Recruiting
This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 50 or 100 mg, and finerenone 10 mg daily. The study duration is 6 months, and participants will be randomized to either polypill therapy or usual care. The primary outcome is change in peak VO2 and adherence to usual care. The investigators hypo... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/09/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Type 2 Diabetes, High Blood Pressure
Register for Updates